公开(公告)号：CA2845806A1

公开(公告)日：2013-03-21

申请号：CA2845806

申请日：2011-09-13

Applicant: PHARMACYCLICS INC ,  SERVIER SAS LAB

Inventor： LOURY DAVID J ,  BUGGY JOSEPH J ,  MODY TARAK D ,  VERNER ERIK J ,  PURRO NORBERT ,  BALASUBRAMANIAN SRIRAM ,  KLOOS IOANA ,  DEPIL STEPHANE

IPC: A61K31/4184 ,  A61K31/16 ,  A61K31/343 ,  A61K31/47 ,  A61P35/00

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

公开(公告)号：CL2012000917A1

公开(公告)日：2012-07-13

申请号：CL2012000917

申请日：2012-04-11

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  MODY TARAK D ,  VERNER ERIK ,  SMYTH MARK STEPHEN ,  LUO WENCHEN

IPC: A61K31/519 ,  A61P19/02 ,  A61P19/10 ,  A61P35/00 ,  C07D487/04

Abstract: Compuestos derivados de pirazolo[3,4-D]pirimidina y sus sales, inhibidores de la tirosina quinasa de Bruton; composición farmacéutica que los comprende, útil para tratar una enfermedad o condición autoinmune tal como artritis reumatoide o lupus, para el tratamiento del cáncer, mastocitosis osteoporosis, entre otras enfermedades.

公开(公告)号：CA2800913A1

公开(公告)日：2011-12-08

申请号：CA2800913

申请日：2011-06-03

Applicant: PHARMACYCLICS INC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：CA2508724A1

公开(公告)日：2004-06-17

申请号：CA2508724

申请日：2003-11-24

Applicant: PHARMACYCLICS INC

Inventor： DOUGLAS CARY ,  FU LEI ,  MODY TARAK D

IPC: C07D487/22 ,  C07F3/02 ,  C07F3/04 ,  C07F5/00 ,  C08F20060101 ,  C08F2/00 ,  C08F8/42

公开(公告)号：PT724457E

公开(公告)日：2003-07-31

申请号：PT94931812

申请日：1994-10-12

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： MAGDA DARREN ,  SESSLER JONATHAN L ,  MODY TARAK D ,  HEMMI GREGORY W ,  HARRIMAN ANTHONY M ,  MILLER RICHARD A ,  KRAL VLADIMIR A

IPC: A61K31/40 ,  A61K31/407 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/02 ,  A61P43/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00 ,  A61P35/00

Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.

公开(公告)号：SI0745085T1

公开(公告)日：2002-12-31

申请号：SI9530608

申请日：1995-02-15

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  MODY TARAK D ,  HEMMI GREGORY W

IPC: A61K49/00 ,  C07D487/22

公开(公告)号：ES2173951T3

公开(公告)日：2002-11-01

申请号：ES95911776

申请日：1995-02-15

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  MODY TARAK D ,  HEMMI GREGORY W

IPC: A61K31/40 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/00 ,  C07D487/22 ,  C07H21/00

Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic pi system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. The addition of substituents to the 12 and 21 positions of the macrocycle offer steric protection for the imine bonds against possible in vivo enzyme hydrolysis. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential and imine bond stabilization are useful in a variety of applications.

公开(公告)号：DK0745085T3

公开(公告)日：2002-06-17

申请号：DK95911776

申请日：1995-02-15

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  MODY TARAK D ,  HEMMI GREGORY W

IPC: A61K31/40 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/00 ,  C07D487/22 ,  C07H21/00

Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic pi system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. The addition of substituents to the 12 and 21 positions of the macrocycle offer steric protection for the imine bonds against possible in vivo enzyme hydrolysis. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential and imine bond stabilization are useful in a variety of applications.

公开(公告)号：CA2434744A1

公开(公告)日：2002-03-07

申请号：CA2434744

申请日：2001-08-28

Applicant: PHARMACYCLICS INC

Inventor： GALANTER JOSHUA ,  MODY TARAK D

IPC: A61K41/00 ,  C07D487/22 ,  C07F5/00 ,  A61K31/395 ,  A61K31/505

Abstract: Novel derivatives a metallotexaphyrins are prepared by modifying the apical ligands associated with the central metal component of metallotexaphyrin.

公开(公告)号：NZ333072A

公开(公告)日：2000-06-23

申请号：NZ33307297

申请日：1997-06-04

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： YOUNG STUART W ,  WRIGHT MEREDITH ,  SESSLER JONATHAN L ,  MODY TARAK D ,  MAGDA DARREN

IPC: C07D487/22 ,  A61K9/127 ,  A61K9/50 ,  A61K31/40 ,  A61K31/409 ,  A61K35/18 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K39/395

Abstract: The isolated texaphyrin-lipophilic molecule-vesicle complex comprises a vesicle loaded with a texaphyrin-lipophilic molecule conjugate. The vesicle portion of the complex can be a liposome or red blood cell and the lipophilic molecule of the complex is estradiol or cholesterol. An antibody having a binding specificity for a photosensitive texaphyrin molecule is disclosed. The isolated texaphyrin-lipophilic molecule-vesicle complex is used in the production of the antibody and diagnosing or treating ocular disorders such as macular degeneration or neovascularization of the eye. The texaphyrin-lipophilic molecule portion can have the formula I or II wherein: M is a divalent or trivalent cation; R1-4, R7 and R8 are independently H, halo, OH, alkyl, alkenyl, alkynyl, aryl, haloalkyl, nitro, formyl, acyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, saccharide, carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, a lipophilic molecule or a linker that is linked to a lipophilic molecule; R6 and R9 are independently are as defined for the groups R1-4, R7 and R8 provided that the halo is not iodide and the haloalkyl is not iodoalkyl; R5 and R10-12 are independently H, alkyl, alkenyl, alkynyl, aryl, hydroxyalkyl, alkoxy, hydroxyalkoxy, hydroxyalkenyl, hydroxyalkynyl, carboxyalkyl, carboxyamide, carboxyamidealkyl, amino, aminoalkyl, a lipophilic molecule or a linker that is linked to a lipophilic molecule; R13 is alkyl, alkenyl, oxyalkyl or hydroxyalkyl having a rotational flexibility around the first bound carbon atom and n is 0 to 5 provided that at least one of R1-12 is a lipophilic molecule or a linker to a lipophilic molecule.